At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
LDV/SOFdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Subjects Undergoing Cancer Chemotherapy
In Brief
A Phase 2 clinical trial evaluating LDV/SOF for Hepatitis C Virus Infection. Completed, enrolled 19 participants across 1 site.
Detailed Summary
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) in treating hepatitis C virus (HCV) infection in pediatric participants who are undergoing cancer chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus Infection
CountriesEgypt
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartAug 2016
Primary CompletionNov 2018
Study CompletionFeb 2019
TodayJul 2026
First PostedAug 16, 2016
Enrollment StartAug 28, 2016
Primary CompletionNov 12, 2018
Study CompletionFeb 3, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.9 years ago
Interventions
LDV/SOFdrug
Tablet(s) administered orally once daily